These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27177227)

  • 1. Tailored chemokine receptor modification improves homing of adoptive therapy T cells in a spontaneous tumor model.
    Garetto S; Sardi C; Martini E; Roselli G; Morone D; Angioni R; Cianciotti BC; Trovato AE; Franchina DG; Castino GF; Vignali D; Erreni M; Marchesi F; Rumio C; Kallikourdis M
    Oncotarget; 2016 Jul; 7(28):43010-43026. PubMed ID: 27177227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An HSV-2 based oncolytic virus can function as an attractant to guide migration of adoptively transferred T cells to tumor sites.
    Fu X; Rivera A; Tao L; Zhang X
    Oncotarget; 2015 Jan; 6(2):902-14. PubMed ID: 25460506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving homing in T cell therapy.
    Vignali D; Kallikourdis M
    Cytokine Growth Factor Rev; 2017 Aug; 36():107-116. PubMed ID: 28690108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effect of lymphotactin and interferon gamma-inducible protein-10 transgene expression in T-cell localization and adoptive T-cell therapy of tumors.
    Huang H; Xiang J
    Int J Cancer; 2004 May; 109(6):817-25. PubMed ID: 15027114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of TGF-β signaling greatly enhances the efficacy of TCR gene therapy of cancer.
    Bendle GM; Linnemann C; Bies L; Song JY; Schumacher TN
    J Immunol; 2013 Sep; 191(6):3232-9. PubMed ID: 23940272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Permissive expansion and homing of adoptively transferred T cells in tumor-bearing hosts.
    Perez C; Jukica A; Listopad JJ; Anders K; Kühl AA; Loddenkemper C; Blankenstein T; Charo J
    Int J Cancer; 2015 Jul; 137(2):359-71. PubMed ID: 25530110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor.
    Moon EK; Carpenito C; Sun J; Wang LC; Kapoor V; Predina J; Powell DJ; Riley JL; June CH; Albelda SM
    Clin Cancer Res; 2011 Jul; 17(14):4719-30. PubMed ID: 21610146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo.
    Hughes DP; Baskar D; Urban FF; Friedman MS; Braun TM; McDonagh KT
    Cytotherapy; 2005; 7(5):396-407. PubMed ID: 16236629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs.
    Zhang Y; Wakita D; Chamoto K; Narita Y; Matsubara N; Kitamura H; Nishimura T
    Int Immunol; 2007 Feb; 19(2):151-61. PubMed ID: 17189593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
    Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ
    BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unbiased chemokine receptor screening reveals similar efficacy of lymph node- and tumor-targeted T cell immunotherapy.
    Pachmayr LO; Muehlbauer A; Flommersfeld S; Graml F; Hoenninger J; von Baumgarten L; Buchholz VR; Grassmann S
    Cancer Immunol Immunother; 2023 Sep; 72(9):3111-3124. PubMed ID: 37301772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
    Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
    Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo targeting of an anti-tumor antibody coupled to antigenic MHC class I complexes induces specific growth inhibition and regression of established syngeneic tumor grafts.
    Donda A; Cesson V; Mach JP; Corradin G; Primus FJ; Robert B
    Cancer Immun; 2003 Aug; 3():11. PubMed ID: 12916958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Ishida K; Primus FJ; Yamaue H
    Int J Cancer; 2007 Feb; 120(3):585-93. PubMed ID: 17096339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.
    Nukiwa M; Andarini S; Zaini J; Xin H; Kanehira M; Suzuki T; Fukuhara T; Mizuguchi H; Hayakawa T; Saijo Y; Nukiwa T; Kikuchi T
    Eur J Immunol; 2006 Apr; 36(4):1019-27. PubMed ID: 16525992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells.
    Sun JB; Eriksson K; Li BL; Lindblad M; Azem J; Holmgren J
    Clin Immunol; 2004 Jul; 112(1):35-44. PubMed ID: 15207780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.
    Yong CS; John LB; Devaud C; Prince MH; Johnstone RW; Trapani JA; Darcy PK; Kershaw MH
    Oncotarget; 2016 Jun; 7(23):34582-98. PubMed ID: 27153556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic limitations in tumor-specific CD8+ memory T cell engraftment.
    Bathe OF; Dalyot-Herman N; Malek TR
    BMC Cancer; 2003 Jul; 3():21. PubMed ID: 12882650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arming tumor-reactive T cells with costimulator B7-1 enhances therapeutic efficacy of the T cells.
    Zheng G; Liu S; Wang P; Xu Y; Chen A
    Cancer Res; 2006 Jul; 66(13):6793-9. PubMed ID: 16818656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Tumor Effects after Adoptive Transfer of IL-12 Transposon-Modified Murine Splenocytes in the OT-I-Melanoma Mouse Model.
    Galvan DL; O'Neil RT; Foster AE; Huye L; Bear A; Rooney CM; Wilson MH
    PLoS One; 2015; 10(10):e0140744. PubMed ID: 26473608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.